East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2501)
07/06/2023

Indication

In combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express programmed death ligand 1 (PD-L1) with a combined positive score (CPS)≥1. SMC restriction: treatment with pembrolizumab is subject...

In combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express programmed death ligand 1 (PD-L1) with a combined positive score (CPS)≥1. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.

Therapeutic Area

Malignant disease and immunosuppression

Status Description

Routinely available in line with national guidance

Formulation

25mg/ml concentrate for solution for infusion

Comments

June 2023 - Routinely available in line with national guidance. Included on the ERF for Specialist Use only.

Link to Advice

SMC2501

Advice Published

13/02/2023

SMC Submission Type

Full

SMC Status

Restricted